Dopaminergic modulation of striatal networks in health and Parkinson's disease

Current Opinion in Neurobiology

Volumn 29, Issue , 2014, Pages 109-117

  Surmeier, D James ^a   Graves, Steven M ^a   Shen, Weixing ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

CHOLINERGIC NERVE CELL; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DYSKINESIA; HUMAN; NERVE CELL; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPINY PROJECTION NEURON; STRIATE CORTEX; SYNAPSE; CORPUS STRIATUM; METABOLISM; PATHOLOGY; PHYSIOLOGY; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BRAIN FUNCTION; BRAIN SIZE; CELL SIZE; CELL STRUCTURE; CELLULAR DISTRIBUTION; DENDRITE; DOPAMINERGIC ACTIVITY; LONG TERM DEPRESSION; NERVE CELL EXCITABILITY; NEUROMODULATION; NEUROMUSCULAR SYNAPSE; PARASYMPATHETIC INNERVATION;

CORPUS STRIATUM; DOPAMINE; HUMANS; NERVE NET; PARKINSON DISEASE; SIGNAL TRANSDUCTION;

EID: 84904636939     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2014.07.008     Document Type: Review

References (72)

1. Wall N.R., De La Parra M., Callaway E.M., Kreitzer A.C. Differential innervation of direct- and indirect-pathway striatal projection neurons. Neuron 2013, 79:347-360.
2. Maia T.V., Frank M.J. From reinforcement learning models to psychiatric and neurological disorders. Nat Neurosci 2011, 14:154-162.
3. Freeze B.S., Kravitz A.V., Hammack N., Berke J.D., Kreitzer A.C. Control of basal ganglia output by direct and indirect pathway projection neurons. J Neurosci 2013, 33:18531-18539.
4. Kravitz A.V., Tye L.D., Kreitzer A.C. Distinct roles for direct and indirect pathway striatal neurons in reinforcement. Nat Neurosci 2012, 15:816-818.
5. Sano H., Chiken S., Hikida T., Kobayashi K., Nambu A. Signals through the striatopallidal indirect pathway stop movements by phasic excitation in the substantia nigra. J Neurosci 2013, 33:7583-7594.
6. Cui G., Jun S.B., Jin X., Pham M.D., Vogel S.S., Lovinger D.M., Costa R.M. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature 2013, 494:238-242.
7. Barroso-Chinea P., Bezard E. Basal ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia. Front Neuroanat 2010, 4.
8. Beaulieu J.-M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011, 63:182-217.
9. Gittis A.H., Kreitzer A.C. Striatal microcircuitry and movement disorders. Trends Neurosci 2012, 35:557-564.
10. Gerfen C.R., Surmeier D.J. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 2011, 34:441-466.
11. Flores-Barrera E., Vizcarra-Chacón B.J., Tapia D., Bargas J., Galarraga E. Different corticostriatal integration in spiny projection neurons from direct and indirect pathways. Front Syst Neurosci 2010, 4:15.
12. Gertler T.S., Chan C.S., Surmeier D.J. Dichotomous anatomical properties of adult striatal medium spiny neurons. J Neurosci 2008, 28:10814-10824.
13. Kreitzer A.C., Malenka R.C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007, 445:643-647.
14. Day M., Wokosin D., Plotkin J.L., Tian X., Surmeier D.J. Differential excitability and modulation of striatal medium spiny neuron dendrites. J Neurosci 2008, 28:11603-11614.
15. Turrigiano G.G. The self-tuning neuron: synaptic scaling of excitatory synapses. Cell 2008, 135:422-435.
16. Chan C.S., Peterson J.D., Gertler T.S., Glajch K.E., Quintana R.E., Cui Q., Sebel L.E., Plotkin J.L., Shen W., Heiman M., et al. Strain-specific regulation of striatal phenotype in Drd2-eGFP BAC transgenic mice. J Neurosci 2012, 32:9124-9132.
17. Cazorla M., Shegda M., Ramesh B., Harrison N.L., Kellendonk C. Striatal D2 receptors regulate dendritic morphology of medium spiny neurons via Kir2 channels. J Neurosci 2012, 32:2398-2409.
18. Nisenbaum E.S., Wilson C.J. Potassium currents responsible for inward and outward rectification in rat neostriatal spiny projection neurons. J Neurosci 1995, 15:4449-4463.
19. Day M., Wang Z., Ding J., An X., Ingham C.A., Shering A.F., Wokosin D., Ilijic E., Sun Z., Sampson A.R., et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 2006, 9:251-259.
20. Gittis A.H., Hang G.B., Ladow E.S., Shoenfeld L.R., Atallah B.V., Finkbeiner S., Kreitzer A.C. Rapid target-specific remodeling of fast-spiking inhibitory circuits after loss of dopamine. Neuron 2011, 71:858-868.
21. Suárez L.M., Solís O., Caramés J.M., Taravini I.R., Solís J.M., Murer M.G., Moratalla R. l-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry 2014, 75:711-722.
22. Zhang Y., Meredith G.E., Mendoza-Elias N., Rademacher D.J., Tseng K.Y., Steece-Collier K. Aberrant restoration of spines and their synapses in l-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses. J Neurosci 2013, 33:11655-11667.
23. Urs N.M., Snyder J.C., Jacobsen J.P.R., Peterson S.M., Caron M.G. Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action. Proc Natl Acad Sci U S A 2012, 109:20732-20737.
24. Fasano C., Bourque M.-J., Lapointe G., Leo D., Thibault D., Haber M., Kortleven C., DesGroseillers L., Murai K.K., Trudeau L.-É. Dopamine facilitates dendritic spine formation by cultured striatal medium spiny neurons through both D1 and D2 dopamine receptors. Neuropharmacology 2013, 67:432-443.
25. Cazorla M., de Carvalho F.D., Chohan M.O., Shegda M., Chuhma N., Rayport S., Ahmari S.E., Moore H., Kellendonk C. Dopamine D2 receptors regulate the anatomical and functional balance of basal ganglia circuitry. Neuron 2014, 81:153-164.
26. Farrell M.S., Pei Y., Wan Y., Yadav P.N., Daigle T.L., Urban D.J., Lee H.-M., Sciaky N., Simmons A., Nonneman R.J., et al. A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons. Neuropsychopharmacology 2013, 38:854-862.
27. Ferguson S.M., Phillips P.E.M., Roth B.L., Wess J., Neumaier J.F. Direct-pathway striatal neurons regulate the retention of decision-making strategies. J Neurosci 2013, 33:11668-11676.
28. Farrell M.S., Roth B.L. Pharmacosynthetics: reimagining the pharmacogenetic approach. Brain Res 2013, 1511:6-20.
29. Mathur B.N., Lovinger D.M. Endocannabinoid-dopamine interactions in striatal synaptic plasticity. Front Pharmacol 2012, 3:66.
30. Wang Z., Kai L., Day M., Ronesi J., Yin H.H., Ding J., Tkatch T., Lovinger D.M., Surmeier D.J. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 2006, 50:443-452.
31. Bagetta V., Picconi B., Marinucci S., Sgobio C., Pendolino V., Ghiglieri V., Fusco F.R., Giampà C., Calabresi P. Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease. J Neurosci 2011, 31:12513-12522.
32. Tozzi A., de Iure A., Di Filippo M., Tantucci M., Costa C., Borsini F., Ghiglieri V., Giampà C., Fusco F.R., Picconi B., et al. The distinct role of medium spiny neurons and cholinergic interneurons in the D2/A2A receptor interaction in the striatum: implications for parkinson's disease. J Neurosci 2011, 31:1850-1862.
33. + channels reduces autonomous activity in striatal cholinergic interneurons. J Neurosci 2004, 24:10289-10301.
34. Calabresi P., Centonze D., Gubellini P., Pisani A., Bernardi G. Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation. Eur J Neurosci 1998, 10:2887-2895.
35. Lerner T.N., Kreitzer A.C. RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits. Neuron 2012, 73:347-359.
36. Shen W., Flajolet M., Greengard P., Surmeier D.J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321:848-851.
37. Shonesy B.C., Wang X., Rose K.L., Ramikie T.S., Cavener V.S., Rentz T., Baucum A.J., Jalan-Sakrikar N., Mackie K., Winder D.G., et al. CaMKII regulates diacylglycerol lipase-α and striatal endocannabinoid signaling. Nat Neurosci 2013, 16:456-463.
38. 2+ signaling in spines. J Neurosci 2014, 34:869-879.
39. 2+ influx by D2 dopamine and A2A adenosine receptors. Nat Neurosci 2010, 13:958-966.
40. Bernard V., Normand E., Bloch B. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J Neurosci 1992, 12:3591-3600.
41. Hersch S.M., Gutekunst C.A., Rees H.D., Heilman C.J., Levey A.I. Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J Neurosci 1994, 14:3351-3363.
42. Yan Z., Flores-Hernandez J., Surmeier D.J. Coordinated expression of muscarinic receptor messenger RNAs in striatal medium spiny neurons. Neuroscience 2001, 103:1017-1024.
43. Atwood B.K., Kupferschmidt D.A., Lovinger D.M. Opioids induce dissociable forms of long-term depression of excitatory inputs to the dorsal striatum. Nat Neurosci 2014, 10.1038/nn.3652.
44. Mathur B.N., Capik N.A., Alvarez V.A., Lovinger D.M. Serotonin induces long-term depression at corticostriatal synapses. J Neurosci 2011, 31:7402-7411.
45. Pascoli V., Turiault M., Lüscher C. Reversal of cocaine-evoked synaptic potentiation resets drug-induced adaptive behaviour. Nature 2012, 481:71-75.
46. Pawlak V., Kerr J.N.D. Dopamine receptor activation is required for corticostriatal spike-timing-dependent plasticity. J Neurosci 2008, 28:2435-2446.
47. Ladépêche L., Dupuis J.P., Bouchet D., Doudnikoff E., Yang L., Campagne Y., Bezard E., Hosy E., Groc L. Single-molecule imaging of the functional crosstalk between surface NMDA and dopamine D1 receptors. Proc Natl Acad Sci U S A 2013, 110:18005-18010.
48. Scott L., Zelenin S., Malmersjö S., Kowalewski J.M., Markus E.Z., Nairn A.C., Greengard P., Brismar H., Aperia A. Allosteric changes of the NMDA receptor trap diffusible dopamine 1 receptors in spines. Proc Natl Acad Sci U S A 2006, 103:762-767.
49. Ortinski P.I., Turner J.R., Pierce R.C. Extrasynaptic targeting of NMDA receptors following D1 dopamine receptor activation and cocaine self-administration. J Neurosci 2013, 33:9451-9461.
50. Park J.M., Hu J.-H., Milshteyn A., Zhang P.W., Moore C.G., Park S., Datko M.C., Domingo R.D., Reyes C.M., Wang X.J., et al. A prolyl-isomerase mediates dopamine-dependent plasticity and cocaine motor sensitization. Cell 2013, 154:637-650.
51. Gonon F. Prolonged and extrasynaptic excitatory action of dopamine mediated by D1 receptors in the rat striatum in vivo. J Neurosci 1997, 17:5972-5978.
52. Castro L.R.V., Brito M., Guiot E., Polito M., Korn C.W., Hervé D., Girault J.-A., Paupardin-Tritsch D., Vincent P. Striatal neurones have a specific ability to respond to phasic dopamine release. J Physiol 2013, 591:3197-3214.
53. Araya R., Andino-Pavlovsky V., Yuste R., Etchenique R. Two-photon optical interrogation of individual dendritic spines with caged dopamine. ACS Chem Neurosci 2013, 4:1163-1167.
54. Howe M.W., Tierney P.L., Sandberg S.G., Phillips P.E.M., Graybiel A.M. Prolonged dopamine signalling in striatum signals proximity and value of distant rewards. Nature 2013, 500:575-579.
55. Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Can Med Assoc J 1962, 87:802-807.
56. Ding J.B., Guzman J.N., Peterson J.D., Goldberg J.A., Surmeier D.J. Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron 2010, 67:294-307.
57. Cachope R., Mateo Y., Mathur B.N., Irving J., Wang H.-L., Morales M., Lovinger D.M., Cheer J.F. Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: setting the tone for reward processing. Cell Rep 2012, 2:33-41.
58. Threlfell S., Lalic T., Platt N.J., Jennings K.A., Deisseroth K., Cragg S.J. Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 2012, 75:58-64.
59. Redgrave P., Vautrelle N., Reynolds J.N.J. Functional properties of the basal ganglia's re-entrant loop architecture: selection and reinforcement. Neuroscience 2011, 198:138-151.
60. Feyder M., Bonito-Oliva A., Fisone G. l-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci 2011, 5:71.
61. Cenci M.A., Konradi C. Maladaptive striatal plasticity in l-DOPA-induced dyskinesia. Prog Brain Res 2010, 183:209-233.
62. Subramaniam S., Napolitano F., Mealer R.G., Kim S., Errico F., Barrow R., Shahani N., Tyagi R., Snyder S.H., Usiello A. Rhes, a striatal-enriched small G protein, mediates mTOR signaling and l-DOPA-induced dyskinesia. Nat Neurosci 2011, 15:191-193.
63. Heiman M., Schaefer A., Gong S., Peterson J.D., Day M., Ramsey K.E., Suárez-Fariñas M., Schwarz C., Stephan D.A., Surmeier D.J., et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell 2008, 135:738-748.
64. Heiman M., Heilbut A., Francardo V., Kulicke R., Fenster R.J., Kolaczyk E.D., Mesirov J.P., Surmeier D.J., Cenci M.A., Greengard P. Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc Natl Acad Sci U S A 2014, 111:4578-4583.
65. Alcacer C., Santini E., Valjent E., Gaven F., Girault J.-A., Hervé D. Gαolf mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in l-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci 2012, 32:5900-5910.
66. Fasano S., Bezard E., D'Antoni A., Francardo V., Indrigo M., Qin L., Doveró S., Cerovic M., Cenci M.A., Brambilla R. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with l-DOPA-induced dyskinesia. Proc Natl Acad Sci U S A 2010, 107:21824-21829.
67. Ahmed I., Bose S.K., Pavese N., Ramlackhansingh A., Turkheimer F., Hotton G., Hammers A., Brooks D.J. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 2011, 134:979-986.
68. Mabrouk O.S., Mela F., Calcagno M., Budri M., Viaro R., Dekundy A., Parsons C.G., Auberson Y.P., Morari M. GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats. ACS Chem Neurosci 2013, 4:808-816.
69. Picconi B., Centonze D., Håkansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat Neurosci 2003, 6:501-506.
70. Picconi B., Bagetta V., Ghiglieri V., Paille V., Di Filippo M., Pendolino V., Tozzi A., Giampà C., Fusco F.R., Sgobio C., et al. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 2011, 134:375-387.
71. Takuma K., Tanaka T., Takahashi T., Hiramatsu N., Ota Y., Ago Y., Matsuda T. Neuronal nitric oxide synthase inhibition attenuates the development of l-DOPA-induced dyskinesia in hemi-parkinsonian rats. Eur J Pharmacol 2012, 683:166-173.
72. Padovan-Neto F.E., Echeverry M.B., Tumas V., Del-Bel E.A. Nitric oxide synthase inhibition attenuates l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neuroscience 2009, 159:927-935.